Determination of Plasma and Intracellular Levels of Nucleoside Reverse Transcriptase Inhibitors (NRTI) and of Nucleotide Analog Tenofovir Disoproxil Fumarate (TDF) in Patients Treated With Abacavir and/or Lamivudine Given With or Without TDF.
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- The primary endpoint will be the variation between the intracellular levels of 3TC and ABC before and after the interruption of the treatment with TDF
研究概览
简要总结
The purpose of this study is to evaluate if there are pharmacokinetic interactions between the NRTI 3TC and ABV, and the TDF nucleotide. For this purpose, the intracellular and plasma levels of 3TC and ABV will be compared in patients given these nucleosides with TDF and 30 days after the interruption of the TDF.
详细描述
There is clear evidence of pharmacokinetic interaction between ddI+TDF. However, the interaction between TDF and other NRTIs, mainly at intracellular level, has not been so well studied.
Since all the NRTIs are anabolized at intracellular level by numerous kinases, and are transported by passive carrier systems, the interaction may be between TDF and other NRTIs.
This study aims to investigate the pharmacokinetic interactions between the TDF and the nucleosides abacavir (ABV) and lamivudine (3TC) at plasma and intracellular level.
With this objective, intracellular and plasma levels will be analysed in a group of patients that receive the combinations 3TC +TDF, ABV+TDF and 3TC+ABV+TDF together with lopinavir/rtv or nevirapine. Subsequently, in a second phase of the study, in the group of patients given ABV and/or 3TC + TDF + lopinavir/rtv, the pharmacokinetic determinations will be repeated after a 4-week interruption of the TDF .
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HIV+ patients aged above 18 years.
- •Undetectable HIV viral load in the last determination
- •Patients capable of correct compliance according to clinical criteria.
- •Patients on triple HAART therapy for the previous 3 months including 3TC and/or ABV and TDF, with a PI (Lopinavir/ritonavir) or an NNRTI (Nevirapine)
- •Women may not be of fertile age (defined as at least one year from menopause or undergoing any surgical sterilisation technique), or must undertake to use a barrier contraceptive method during the study.
- •Ability to provide informed consent.
排除标准
- •Incorrect therapeutic compliance over the four weeks before the beginning of the study.
- •Interruption or withdrawal from therapy during follow-up.
- •Concomitant treatment with any drug which according to the clinician's criterion may interact with the investigational antiretrovirals, such as other antiretrovirals.
- •Triple HAART therapy including Nevirapine (for phase II)
- •Documented or suspected resistance to ABV, 3TC or lopinavir/rtv (for phase II).
研究组 & 干预措施
1
Phase I: 3TC + TDF + NVP or LPV/rtv
Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: 3TC + LPV/rtv
干预措施: Patients in treatment with 3TC + TDF + LPV/rtv, stop tenofovir during 4 weeks (Drug)
2
Phase I: ABV + TDF + NVP or LPV/rtv
Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: ABV + LPV/rtv
干预措施: Patients in treatment with ABV + TDF + LPV/rtv, stop tenofovir during 4 weeks (Drug)
3
Phase I: 3TC + ABV + TDF + NVP or LPV/rtv
Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: 3TC + ABV + LPV/rtv
干预措施: Patients in treatment with 3TC + ABV + TDF+ LPV/rtv, stop TDF during 4 weeks (Drug)
结局指标
主要结局
The primary endpoint will be the variation between the intracellular levels of 3TC and ABC before and after the interruption of the treatment with TDF
时间窗: At baseline and week 4.
次要结局
- Variations between the plasma levels of 3TC and ABC before and after interruption of the treatment with TDF.(at baseline and week 4)
- Correlation between the intracellular and plasma levels of 3TC, ABC and TDF.(at baseline and week 4)
- Changes in the intracellular levels of TDF following the withdrawal of the drug.(At week 4.)